@article {ANAMI2583, author = {SHIMPEI ANAMI and JUNYA FUKAI and MIZUKI HAMA and AZUSA AWAYA and TAKAYA INAGAKI and TAKAHIRO CHIBA and YASUTAKA NODA and YONEHIRO KANEMURA and NAOYUKI NAKAO and TETSUO SONOMURA}, title = {Brainstem Infiltration Predicts Survival in Patients With High-grade Gliomas Treated With Chemoradiotherapy}, volume = {41}, number = {5}, pages = {2583--2589}, year = {2021}, doi = {10.21873/anticanres.15037}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: High-grade gliomas have a poor prognosis despite standard treatment. The aim of the study was to identify new prognostic factors to select patients who need more intense treatment. Patients and Methods: Forty-three consecutive patients underwent surgery plus chemoradiotherapy for pathologically diagnosed high-grade gliomas (grade III, IV). Results: The median survival time was 989 days, and the 1-year survival rate was 87.6\%. Among patients with grade IV disease, the median survival time, 1-year, and 2-year survival rate were 814 days, 82.6\%, and 58.7\%, respectively. In the univariate analysis, unmethylated MGMT promoter (p=0.0495), brainstem infiltration (p=0.0004), basal ganglia as the primary lesion site (p=0.0056), 3-dimensional conformal radiotherapy (p=0.0286), and \<50 Gy (p=0.0049) were associated with a poor prognosis. In the multivariate analysis, only brainstem infiltration retained significance (HR for death, 0.21; 95\% CI=0.06-0.70; p=0.011). Conclusion: Brainstem infiltration is a novel prognostic factor for poor prognosis in patients with high-grade gliomas.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/41/5/2583}, eprint = {https://ar.iiarjournals.org/content/41/5/2583.full.pdf}, journal = {Anticancer Research} }